Kopran has obtained registration approval for its formulation product in South Africa. In a notice to the Bombay Stock Exchange (BSE), Kopran said that it has received a major boost for its international operations with the approval of the registration of its brand Bren-400 (ibuprofen tablets) by the Medicines Control Council (MCC) of South Africa.
Further, to strengthen its international formulations business operations in South Africa, Kopran has entered into an strategic alliance with Be-Tabs - one of the leading generic pharmaceutical companies in South Africa.
Kopran and Be-Tabs have entered into a long-term agreement for both